NIKA PHARMACEUTICALS, INC.: 10-Q filed 2024-05-28

Name: NIKA PHARMACEUTICALS, INC.: 10-Q filed 2024-05-28
Creator: NIKA PHARMACEUTICALS, INC.

What NIKA PHARMACEUTICALS, INC. reported in its quarterly report filed 2024-05-28 (fiscal Q1 2024): 23 published measures, 48 facts as tagged in accession 0001826466-24-000068.

This filing

Form: 10-Q (quarterly report)
Filed: 2024-05-28
Fiscal period: fiscal Q1 2024
Accession: 0001826466-24-000068 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All NIKA PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2024-03-31	41,473	USD
At 2023-12-31	19,596	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2024-03-31	265,955	USD
At 2023-12-31	101,745	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2024-03-31	-224,482	USD
At 2023-12-31	-82,149	USD
At 2023-03-31	-36,886	USD
At 2022-12-31	-17,316	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2024-03-31	24,466	USD
At 2023-12-31	19,596	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	-65,988	USD	91
2023-01-01 to 2023-03-31	-19,570	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	-150,007	USD	91
2023-01-01 to 2023-03-31	-19,570	USD	90

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	154,877	USD	91
2023-01-01 to 2023-03-31	23,165	USD	90

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2024-03-31	-8,930,864	USD
At 2023-12-31	-3,400,247	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	876,090,000	shares	91
2023-01-01 to 2023-03-31	876,090,000	shares	90

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	876,090,000	shares	91
2023-01-01 to 2023-03-31	876,090,000	shares	90

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	0	USD/shares	91
2023-01-01 to 2023-03-31	0	USD/shares	90

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	0	USD/shares	91
2023-01-01 to 2023-03-31	0	USD/shares	90

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	-65,988	USD	91
2023-01-01 to 2023-03-31	-19,570	USD	90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2024-03-31	41,473	USD
At 2023-12-31	19,596	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2024-03-31	265,955	USD
At 2023-12-31	101,745	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	65,988	USD	91
2023-01-01 to 2023-03-31	19,570	USD	90

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

Period	Value	Unit	Days
At 2024-03-31	17,007	USD

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2024-03-31	876,090,000	shares
At 2023-12-31	876,090,000	shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

Period	Value	Unit
At 2024-03-31	24,466	USD
At 2023-12-31	19,596	USD
At 2023-03-31	4,459	USD
At 2022-12-31	864	USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2024-03-31	8,617,773	USD
At 2023-12-31	3,229,489	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	-65,988	USD	91
2023-01-01 to 2023-03-31	-19,570	USD	90

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	65,988	USD	91
2023-01-01 to 2023-03-31	19,570	USD	90

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	17,007	USD	91

Inspect the source

Entity: NIKA PHARMACEUTICALS, INC. / CIK 0001145604
Captured: 2026-09-20T07:42:29.079Z
SEC response SHA-256: 72455d4e19d0f82286a99d0fa349659ab1ab793431c0cac82c5fb18286c89242

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001145604.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))